Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination - PubMed (original) (raw)
Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination
Joanna Galea-Lauri et al. Cancer Immunol Immunother. 2002 Aug.
Abstract
Dendritic cells (DC) have been successfully used in clinical pilot studies to induce tumor-specific immunity as well as clinical response in selected patients. However, DC-based immunotherapy remains a challenge and several parameters need to be examined in order to optimize the induction of anti-tumor immune responses. This study focuses on DC vaccination for leukemia and evaluates the in vitro efficacy of three different strategies for generating antigen-loaded DC-based vaccines for the induction of major histocompatibility complex (MHC) class I-restricted anti-leukemia cytotoxic T lymphocyte (CTL) responses. These included direct fusion of DC with leukemia cells to generate DC-leukemia cell hybrids, and DC pulsed with either apoptotic leukemia cell fragments or whole tumor cell lysates. Using either the U937 cell line or primary human acute myeloid leukemia blasts (AML), DC-leukemia cell hybrids were found to be the most potent in vitro inducers of CTL activity. DC pulsed with apoptotic tumor cell fragments were less efficient, but induced a more potent CTL response compared to tumor lysate-pulsed DC. The CTL responses were both MHC class I-restricted and antigen-specific, as shown by the inability of the CTL to lyse other control targets. The data presented here suggest that the method of antigen loading onto DC may be critical in the design of tumor vaccines.
Similar articles
- [Investigation on specific killing acute leukemia cell reaction of the cytotoxic T lymphocyte induced by dendritic cell pulsed with frozen-thawed antigen].
He B, Qiu G, Xie X. He B, et al. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2004 Dec;21(6):974-8. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2004. PMID: 15646345 Chinese. - Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization.
Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Houtenbos I, et al. Immunobiology. 2005;210(2-4):249-57. doi: 10.1016/j.imbio.2005.05.019. Immunobiology. 2005. PMID: 16164032 Review. - Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
Pyzer AR, Avigan DE, Rosenblatt J. Pyzer AR, et al. Hum Vaccin Immunother. 2014;10(11):3125-31. doi: 10.4161/21645515.2014.982993. Hum Vaccin Immunother. 2014. PMID: 25625926 Free PMC article. Review.
Cited by
- A novel anti-CTLA-4 nanobody-IL12 fusion protein in combination with a dendritic cell/tumour fusion cell vaccine enhances the antitumour activity of CD8+ T cells in solid tumours.
Jiang MJ, Cui HP, Li TT, Yang XM, Lu XL, Liu AQ. Jiang MJ, et al. J Nanobiotechnology. 2024 Oct 19;22(1):645. doi: 10.1186/s12951-024-02914-6. J Nanobiotechnology. 2024. PMID: 39427185 - A Novel Heat Shock Protein 70-Based Vaccine Prepared from DC Tumor Fusion Cells: An Update.
Weng D, Calderwood SK, Gong J. Weng D, et al. Methods Mol Biol. 2023;2693:209-219. doi: 10.1007/978-1-0716-3342-7_16. Methods Mol Biol. 2023. PMID: 37540437 - A versatile photothermal vaccine based on acid-responsive glyco-nanoplatform for synergistic therapy of cancer.
Gao Y, Zhao Q, Xiao M, Huang X, Wu X. Gao Y, et al. Biomaterials. 2021 Jun;273:120792. doi: 10.1016/j.biomaterials.2021.120792. Epub 2021 Apr 8. Biomaterials. 2021. PMID: 33872856 Free PMC article. - Targeting and Specific Activation of Antigen-Presenting Cells by Endogenous Antigen-Loaded Nanoparticles Elicits Tumor-Specific Immunity.
Chang HC, Zou ZZ, Wang QH, Li J, Jin H, Yin QX, Xing D. Chang HC, et al. Adv Sci (Weinh). 2019 Nov 8;7(1):1900069. doi: 10.1002/advs.201900069. eCollection 2020 Jan. Adv Sci (Weinh). 2019. PMID: 31921548 Free PMC article. - Can Dendritic Cell Vaccination Prevent Leukemia Relapse?
O'Brien LJ, Guillerey C, Radford KJ. O'Brien LJ, et al. Cancers (Basel). 2019 Jun 22;11(6):875. doi: 10.3390/cancers11060875. Cancers (Basel). 2019. PMID: 31234526 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials